PD-1 Combined With IMRT in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of PD-1 immune checkpoint inhibitor combined with IMRT in
the treatment of intermediate-risk nasopharyngeal carcinoma (T2-3N0 or T1-2N1 stage and
EBV-DNA≤4000 copy/ml).